Resistance analyses in highly treatment-experienced patients treated with etravirine in a roll-over study confirm the results from the Phase III DUET studies

Highly treatment-experienced HIV-1-infected patients with few treatment options were enrolled from DUET into TMC125-C217 and received 200 mg twice-daily etravirine and a background regimen (BR), including 600/100 mg twice-daily darunavir/ritonavir with [greater than or equal]1 approved antiretroviral drug. Etravirine resistance was explored in the group of etravirine-naive patients who enrolled from the DUET placebo group; patients either discontinued or completed DUET. Most (32/39) DUET-completers enrolled in TMC125-C217 with undetectable viral load (VL) and without available resistance information at baseline. Therefore, this analysis focused on DUET-discontinuers; development of resistance to etravirine was analysed in virological failures (VFs) with available genotypic and phenotypic data. Study TMC125-C217 enrolled highly treatment experienced patients who started on an etravirine-containing regimen as one of few treatment options. In patients with VF, the emerging etravirine resistance profile was consistent with the one described previously in the DUET studies.